Vertex Pharmaceuticals Inc. (VRTX) EVP Stuart A. Arbuckle Sells 1,208 Shares of Stock
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) EVP Stuart A. Arbuckle sold 1,208 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $86.46, for a total value of $104,443.68. Following the completion of the sale, the executive vice president now directly owns 114,566 shares in the company, valued at approximately $9,905,376.36. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) traded up 0.36% during mid-day trading on Friday, hitting $85.27. The stock had a trading volume of 177,842 shares. Vertex Pharmaceuticals Inc. has a 12 month low of $75.90 and a 12 month high of $134.71. The company’s market cap is $21.13 billion. The firm’s 50-day moving average is $93.13 and its 200 day moving average is $89.80.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.24 EPS for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.03. The company earned $431.61 million during the quarter, compared to the consensus estimate of $428.08 million. Vertex Pharmaceuticals had a negative return on equity of 12.34% and a negative net margin of 17.77%. Vertex Pharmaceuticals’s revenue was up 159.9% on a year-over-year basis. During the same period last year, the business posted ($0.54) earnings per share. Equities analysts anticipate that Vertex Pharmaceuticals Inc. will post $0.89 EPS for the current fiscal year.
Several research analysts have weighed in on the company. Zacks Investment Research lowered Vertex Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, September 27th. Maxim Group reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, September 29th. Cowen and Company reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, July 28th. BMO Capital Markets reaffirmed a “hold” rating and set a $87.00 price target on shares of Vertex Pharmaceuticals in a research report on Thursday, September 15th. Finally, Stifel Nicolaus lowered their price target on Vertex Pharmaceuticals from $108.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, August 16th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $117.60.
Several hedge funds have recently modified their holdings of the stock. Aviva PLC increased its stake in shares of Vertex Pharmaceuticals by 1.1% in the first quarter. Aviva PLC now owns 135,620 shares of the pharmaceutical company’s stock worth $10,780,000 after buying an additional 1,456 shares during the last quarter. NN Investment Partners Holdings N.V. acquired a new stake in shares of Vertex Pharmaceuticals during the first quarter worth approximately $2,334,000. Howard Hughes Medical Institute increased its stake in shares of Vertex Pharmaceuticals by 13.0% in the first quarter. Howard Hughes Medical Institute now owns 2,000 shares of the pharmaceutical company’s stock worth $159,000 after buying an additional 230 shares during the last quarter. BlackRock Japan Co. Ltd increased its stake in shares of Vertex Pharmaceuticals by 3.0% in the first quarter. BlackRock Japan Co. Ltd now owns 311,284 shares of the pharmaceutical company’s stock worth $24,744,000 after buying an additional 8,992 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. increased its stake in shares of Vertex Pharmaceuticals by 1.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 6,338,154 shares of the pharmaceutical company’s stock worth $503,820,000 after buying an additional 86,478 shares during the last quarter. 96.19% of the stock is owned by institutional investors.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.